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Abstract
The preservative effects of low temperature on biological materials have been long recognised, and
cryopreservation is now widely used in biomedicine, including in organ transplantation, regenerative medicine and
drug discovery. The lack of organs for transplantation constitutes a major medical challenge, stemming largely from
the inability to preserve donated organs until a suitable recipient is found. Here, we review the latest
cryopreservation methods and applications. We describe the main challenges—scaling up to large volumes and
complex tissues, preventing ice formation and mitigating cryoprotectant toxicity—discuss advantages and
disadvantages of current methods and outline prospects for the future of the field.
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The origins of cryopreservation
Cryopreservation is the storage of biological material at
low temperatures. Since ancient times, it has been
known that biological material can be preserved longer
at low temperatures. Indeed, archaeological findings in-
dicate that as early as 2000 BC, icehouses were used
throughout Mesopotamia to store foods [1]. The preser-
vative effect of cold was also a topic of interest to the
early experimentalists of the seventeenth century, most
notably Boyle [2], who commented on the ability of ice
to preserve human bodies and made several attempts to
freeze and revive live animals, discovering species of
frogs and fish that could survive encasement in ice.
Whereas Boyle could only speculate on the nature of
cold, the intervening centuries have revealed its preser-
vative effect lies in depriving biological systems of the
thermal energy required for normal molecular motion
and metabolism, in turn slowing cellular processes and
decomposition. The ability to reliably generate the ex-
tremely low temperatures required for long-term preser-
vation, typically below − 100 °C, came with the
development of cryogenic technologies at the turn of the
twentieth century. The modern cryopreservation of liv-
ing systems, in the sense of biotechnology, can be traced
to the discovery of the first effective cryoprotective
agents (CPAs), otherwise known as “cryoprotectants”, in
the 1940s [3]. Notably, Lovelock provided crucial early
insights into the origins of cryoinjury and the action of
CPAs [4, 5]. Later work by Mazur pioneered the applica-
tion of quantitative models to describing cell changes
during cooling [6] and paved the way towards theoretical
approaches to studying cryopreservation.
The discipline of cryopreservation is now well estab-
lished as a practical means of storing living cells and tis-
sues and has grown to find applications throughout
biology and medicine. As this review will highlight, cryo-
preservation now holds the potential to strongly benefit
several areas of medicine by increasing the ease with
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: r.bauer@surrey.ac.uk; jp@senescence.info
†Sanja Bojic and Alex Murray should be considered joint first authors, and
Roman Bauer and João Pedro de Magalhães should be considered joint
senior authors.
10Department of Computer Science, University of Surrey, Guildford, UK
11Integrative Genomics of Ageing Group, Institute of Ageing and Chronic
Disease, University of Liverpool, Liverpool, UK
Full list of author information is available at the end of the article
Bojic et al. BMC Biology           (2021) 19:56 
https://doi.org/10.1186/s12915-021-00976-8
which therapeutic cells, tissues, and organs can be
stored.
The challenge of low temperatures
Before discussing the medical applications and oppor-
tunities of cryopreservation, we should first consider the
physiological effects of low temperatures, and the chal-
lenges they present.
Human cells have evolved to operate within an ex-
tremely narrow temperature range. Prolonged or ex-
treme exposure to temperatures below the
normothermic range of 36–38 °C is frequently harmful,
as evidenced by hypothermia and frostbite. Despite this,
sub-zero temperatures are not intrinsically pathogenic.
The damage associated with low temperatures is, for the
most part, the result of uncontrolled transitions between
normothermic and low-temperature regimes. Therefore,
the successful storage and revival of cells depend critic-
ally on the ability to induce and reverse low-temperature
states in a controlled manner that minimises or amelio-
rates transition-related damage. Although this require-
ment is easy to state, it is in practice the central
challenge of cryopreservation.
How does the transition to low temperatures damage
cells? Although numerous routes exist, much of the
damage is driven, either directly or indirectly, by ice for-
mation. In this context, nucleation denotes the first step
in crystallisation as it initiates the growth of ice crystals.
At typical rates of cooling, ice first forms in the
extracellular spaces of tissues (Fig. 1). Ice excludes sol-
utes, meaning that the extracellular solute concentration
increases as water is removed from the extracellular fluid
to form ice crystals. The resultant osmotic gradient
across the cell membranes works to drive water out of
the cells by osmosis, dehydrating cells and increasing the
intracellular solute concentration. This increased solute
concentration depresses the intracellular freezing point,
preventing intracellular ice formation. This process can
damage tissues through two routes: (1) solutes such as
salts, which are maintained at safe concentrations under
normal conditions, become more concentrated to induce
osmotic stress [5]; (2) extracellular ice directly damages
tissues, either by puncturing or crushing cell membranes
or disrupting extracellular structures [7, 8]. However,
the relative significance and interdependence of these
two routes are still not entirely resolved.
If a sample is cooled too quickly for water to exit a
cell, intracellular ice formation can occur. Intracellular
ice crystals are much more damaging than their extracel-
lular counterparts as they are capable of disrupting the
cell’s internal structures, like lysosomes [9]. Intracellular
ice formation is usually, but not always, lethal [10, 11].
Factors affecting lethality include the size of the ice crys-
tals, their intracellular location, their mechanism of
growth, their shape (cubic vs. hexagonal) and the warm-
ing rate [12–14].
To reduce the extent of ice-related damage, cryo-
preservation protocols usually employ CPAs [15]. CPAs
Fig. 1 An overview of the mechanisms of cryopreservation and CPAs. Cryopreservation utilises either slow cooling, in which the sample is frozen
at a controlled rate to allow water to flow out of the cell and prevent intracellular ice formation, or vitrification in which a high freezing rate and/
or high CPA concentration prevents ice formation in the sample. Ice growth can be further controlled by ice nucleation inhibitors, controlled ice
nucleation, ice growth inhibitors or ice recrystallization inhibitors. Devitrification occurs when a vitrified sample is warmed too slowly, resulting in
ice formation. Apoptosis inhibitors may also be utilised to prevent cells from dying after cryopreservation from stress-induced apoptosis
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act to reduce the aforementioned damage via a number
of actions, many of which have not yet been fully identi-
fied. Some main effects are those of reducing the con-
centration of electrolytes [5] and also reducing ice
formation by hydrogen bonding with water molecules to
prevent them from bonding to ice crystals [16]. CPAs
capable of crossing cell membranes are of particular
value. The use of such molecules, termed penetrating
CPAs (pCPAs), can substantially reduce cryoinjury. The
discovery of pCPAs dates back more than 70 years to
when the cryoprotective effects of glycerol were discov-
ered. In their landmark study, Polge et al. discovered
that glycerol improved the revival of spermatozoa from
sub-zero temperatures [17]. Glycerol remains a com-
monly used pCPA, with other notable examples being
propylene glycol (PG), ethylene glycol (EG) and dimethyl
sulfoxide (DMSO).
The cellular protection afforded by CPAs has made
the cryopreservation of cells and simple tissues a routine
procedure; however, there are still several challenges to
be surmounted in the preservation of complex tissues
and organs. Work to categorise these challenges has
identified six broad areas of need [18]. These include: (1)
improved control over ice formation; (2) methods to re-
duce CPA toxicity, to allow their use at higher concen-
trations; (3) the elimination of thermo-mechanical
stresses; (4) methods to prevent or reverse ischemic in-
jury prior to or following preservation; (5) the preven-
tion of chilling injuries; and (6) the development of safe
protocols for organ revival. These will be discussed in
the following sections, along with the initial progress to-
wards their solutions.
Here, we first review the importance of medical cryo-
preservation followed by the major cryopreservation
methods, including slow cooling and vitrification and
discussing their strengths and weaknesses; then, we dis-
cuss the key specific aspects of cryopreservation and tis-
sue damage. Lastly, we discuss the challenges and
avenues for future research.
The medical need for cryopreservation
Organ and tissue preservation
Cryopreservation has multiple and important applica-
tions, particularly in medicine. The fact that it can sig-
nificantly slow down all biochemical reaction kinetics
renders cryopreservation highly attractive as a means to
preserve organs and therefore facilitate the transplant-
ation process. The lack of organ availability constitutes a
major challenge and a significant medical burden for so-
ciety. According to the World Health Organization
(WHO), only 10% of the worldwide need for organ
transplantation was met in 2010 [19]. The lack of trans-
plantable organs stems partially from a shortage of suit-
able donated organs, but more importantly from the
lack of preservation capability. Although the number of
transplanted organs is much lower than what is actually
needed worldwide, it was estimated that approximately
two thirds of potential donor hearts are discarded [20].
Moreover, up to 20% of potential donor kidneys end up
being discarded in the USA [21, 22], and up to 50% of
donated pancreases in the UK [23], primarily due to the
limited time available to find suitable recipients. This ex-
tensive waste could be largely prevented by increasing
the time through advancing preservation methods [24],
especially cryopreservation, which is currently the only
true long-term preservation solution. The potential of
organ and tissue preservation to transform medicine has
recently been reviewed by Giwa and co-workers [25].
The growing shortage of donor organs has become a
central problem limiting the effectiveness of transplant-
ation. Advancing preservation technologies can ultim-
ately benefit many thousands of people worldwide by
increasing local and global access to transplantation, by
improving transplantation outcomes and stimulating
progress in related areas such as immune tolerance in-
duction and xenotransplantation [26]. Prolongation of
preservation times would enable transportation of or-
gans to wider geographical areas, comprehensive evalu-
ation of donor tissues and better graft characterisation
[27]. Notably, the potential public health impact of im-
proved organ banking capability would benefit many
areas of medicine by the banking of organs as well as
other complex tissues, improving not only transplant-
ation but also tissue engineering, trauma medicine,
oncofertility, basic biomedical research and drug discov-
ery [18].
Pharmaceutical research
The ability to bank large quantities of tissues and cells is
of immense interest for the discovery, development and
evaluation of drugs. In particular, drug discovery and
testing could benefit from cryopreservation of tissue
slices. Tissue slices represent a powerful in vitro tool for
studying biological processes as they closely resemble
the organ from which they were derived, containing all
specific cell types present in the organ. Much effort has
been put into optimising the preparation and culturing
techniques of various tissue slices such as liver, brain, in-
testinal and kidney slices [28–31]. Under optimal condi-
tions, tissue slices can be kept viable for at least 24 h
after thawing [32]. The cryopreservation of tissue slices
greatly facilitates their use in pharmaco-toxicological re-
search, leading to efficient use of human organ material
and a decrease of laboratory animal use [32].
Human tissues grown from stem cells are also of high
interest for the pharmaceutical industry. They can en-
able large-scale drug screening tests on human tissues,
facilitate the identification of adverse effects of drugs
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and thus revolutionise toxicology screening [33] and
drug discovery [34, 35]. Given the costs associated with
drug development [36], improved cryopreservation cap-
ability would also constitute an advance for the pharma-
ceutical industry. For animal welfare, the scenario of




Cryopreservation has become a well-established method
for preserving cells and tissues [37], including sperm,
oocytes and ovarian and embryonic tissue which are
now cryopreserved on a large scale. Currently, the main
approaches for cryopreservation are freezing (i.e. the li-
quid phase changes to a solid crystalline phase) and vit-
rification (i.e. the solidification to a glass-like state
without ice formation), as illustrated in Fig. 1. The
methods of freezing and vitrification are commonly dis-
tinguished by whether during sample-cooling ice crystal
growth occurs or is suppressed, respectively (Fig. 2).
Notably, freezing is applied for a wide range of sample
volumes, whilst vitrification usually has a small applica-
tion size.
In freezing, a too low cooling rate can give rise to
cryoinjury due to solution effects. On the other hand,
the rate needs to be slow enough so that there is suffi-
cient time for the water to exit cells, to prevent intracel-
lular ice formation. Freezing usually involves slow
cooling protocols with cooling rates of approximately
1 °C/min [38]. However, different cell types have differ-
ent optimal cooling rates [39].
Vitrification is a separate physical process from freez-
ing and occurs at the so-called “glass transition
temperature”, around − 80 to − 130 °C. In vitrification,
samples solidify with no ice crystal formation (Fig. 3). It
has been previously shown that the vitrification of small
biological samples can be achieved without CPAs using
extremely high cooling rates, e.g. with human sperm
[40]. In larger living systems where an extremely high
cooling rate cannot be achieved, a large percentage of
the water in the sample must be replaced by a vitrifying
CPA to avoid the damaging effects of ice formation. Vit-
rification ultimately forms a stable glass-like state, pre-
serving the molecular contents indefinitely [41].
Fig. 2 How cryoprotective agents (CPAs) work. A When a sample is cooled, ice first forms in the extracellular space. Ice excludes solutes, so the
extracellular solute concentration increases as extracellular water becomes part of the ice crystals. Intracellular water is then drawn out of the cells
via osmosis. B In unprotected cells, the intracellular solute concentration increases and causes damage. C Penetrating CPAs permeate the cell
membrane and increase the intracellular solute concentration which prevents water loss and dilutes other solutes inside the cell which can cause
damage at high concentrations. Ice blockers bind to ice crystals, preventing them from growing, or to nucleators, which prevents heterogenous
ice nucleation. D1, D2 Penetrating CPAs interfere with homogenous ice nucleation by colligative interference, which depresses the freezing point
of the solution. D1 Water forms a regular ice lattice. D2 A CPA molecule disrupts the hydrogen bonding between water molecules
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Importantly, warming after cryopreservation can
lead to injury due to ice crystal formation, which can
occur both after freezing or vitrification. Along these
lines, “ice recrystallization” denotes this damaging
process of large ice crystal growth during thawing of
frozen cells or tissue. Notably, and somewhat
counterintuitively, “devitrification” denotes the process
of crystallisation during warming and after vitrifica-
tion. Hence, devitrification does not mean the process
of warming of a vitrified solution, but the formation
or recrystallization of ice crystals during rewarming.
In vitrification, CPAs are primarily used to inhibit
ice formation by depressing the freezing point of the
solution and increasing its viscosity and the glass
transition temperature. In this way, CPAs decrease
the critical cooling rate for vitrification (Vccr) [42],
allowing the sample to solidify before ice formation
can occur [43]. Notably, CPAs can also impact on the
critical warming rates and so reduce the risk of devit-
rification. What are the requirements for tissues to
vitrify and undergo a transition into the glass-type
state? Most importantly, the cooling rate has to be
sufficiently high, so that ice formation is prevented.
Notably, vitrification requires very high concentrations
of CPAs to lower Vccr to practical levels. Unfortu-
nately, the toxic impact on cells caused by these con-
centrated CPAs is problematic [44]. This problem can
to some extent be mitigated, as discussed ahead in
the "Cryoprotective agents (CPAs)" section.
Although slow cooling and vitrification are well-
established and are used for various applications, they
each have their advantages and disadvantages. For in-
stance, the recording of slow cooling protocols is
practical which facilitates the demonstration of compli-
ance with standard operating procedures and Good
Manufacturing Practice. However, it often requires rela-
tively costly equipment [45]. Moreover, although slow
cooling is more time consuming, this apparent disadvan-
tage can entail a more homogeneous distribution of
CPAs [46], which need to diffuse through and permeate
the extracellular space to take full effect. Also, the slower
and more controlled cooling process in slow cooling is
better suited for quantifiable and reproducible protocols.
The temperature dynamics within the sample volume
are therefore more amenable to modelling in a quantita-
tive manner. However, extracellular ice formed during
slow cooling can also have adverse effects. It remains to
be investigated how such damage depends on cooling
and thawing rates, as well as CPAs.
Rapid cooling to below the glass transition
temperature and/or rapid warming from below the glass
transition temperature during the warming process may
induce fracturing of the glass in which the biological sys-
tem is embedded [43, 47, 48]. Cell-type or tissue-specific
cooling and warming rates can potentially avoid the
problems of devitrification and recrystallisation, and fur-
ther research is required to elaborate on such solutions
(more information can be found in Fahy and Wowk,
2015, p. 45). Notably, such highly adapted protocols can
be problematic with regard to the cryopreservation of
organs comprising different cell or tissue types.
Table 1 summarises the key differences between these
main approaches. Importantly, there is no gold standard
in cryopreservation, and different labs often employ their
own cryogenic processing protocols that might substan-
tially differ from other labs’ approaches.
Fig. 3 A vitrified substance (left) is formed when liquid transitions into a highly viscous, glass-like state that prevents translational molecular
motion. In vitrification, molecules remain in the position they were in when the substance was vitrified. This is different to freezing (right), in
which ice crystals progressively grow as the temperature is decreased, excluding solutes and thus causing the solute concentration to increase
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Directional freezing and directional vitrification
Directional freezing (also called directional solidification)
is a method in which a temperature gradient is used to
cause the progressive growth of ice along the
temperature gradient (Fig. 4). This can be achieved by
moving the sample along the gradient at a controlled
velocity or by placing the sample between two thermo-
conductive blocks. In conventional freezing, the latent
heat of fusion released during freezing is conducted
through the frozen portion of the sample, this may cause
it to melt and can result in repeated freeze-thaw cycles
which can cause increased cellular damage. The morph-
ology and rate of ice growth are uncontrolled and non-
uniform. In directional freezing, heat is removed by con-
duction through the unfrozen portion of the sample,
preventing damage by freeze-thaw cycles. The direc-
tional ice growth results in the formation of lamellae
with cells trapped between them, reducing mechanical
damage [49]. Directional freezing also allows for faster
cooling without inducing intracellular ice formation [50].
Directional freezing has been used to cool a rat’s hind
limb to − 140 °C before submersion in liquid nitrogen
(LN2). The hind limbs were then successfully revived
and re-transplanted onto the rats. Whilst these limbs
were non-functional due to the motor neurons having
been severed during amputation, the limbs were other-
wise viable [51]. Directional freezing has also been used
for the successful cryopreservation of a pig’s liver at −
20 °C. The liver was later revived and attached to an-
other pig by auxiliary transplantation and demonstrated
normal bile production and blood flow [52].
A related technique is directional vitrification; this is
achieved using the same principle as directional freezing,
but with a very high cooling rate. Information on direc-
tional vitrification is limited; however, this technique
may allow for vitrification with cryoprotectant concen-
trations as low as 17.5% PG [53].
Both directional freezing and directional vitrification
are rich avenues for future research. Further work on
directional freezing should aim to further lower the
temperature to which organs can be frozen to − 130 °C,
the temperature at which storage without degradation
can be achieved for centuries or millennia [54].
Key aspects of cryogenic processing protocols
Cooling
As mentioned above, during slow cooling, extracellular
water freezes first and cells lose water due to osmotic
pressure, with more solute outside than inside the cells.
During fast cooling, the transmembrane transport of
water is not fast enough, and the intracellular water is
more likely to freeze as well [55]. It is a complex prob-
lem to determine how quickly to best cool cells and tis-
sues: the optimal cooling rate minimises the dangers of
injury due to high solute concentrations as well as intra-
cellular ice formation. This “sweet spot” depends on
various aspects, including biophysical cell membrane
properties, the volume of the sample, the CPA type and
the concentration.
When cooling a macroscopic sample, e.g. a 2-mL cell
suspension, the large heat capacity of water causes the
Table 1 Comparison of typical key aspects of slow cooling and vitrification
Feature Slow cooling Vitrification
Duration Long (h) Short (s)
Usage of CPAs Low concentrations High concentrations
Costly components Equipment Operation
Controllability/reproducibility/recordability High Low
Operation skills required Low High
Main risks Extracellular ice formation,
osmotic damage
Intracellular ice formation, CPA toxicity,
fracturing, osmotic stress
Fig. 4 In directional freezing, cold is applied to one side of the
sample causing a temperature gradient. Uniform ice lamellae form
along this gradient with heat being conducted through the
unfrozen part of the sample
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core of the sample to cool more slowly than the surface.
The sample therefore usually nucleates in the surface re-
gion first because it is closer to the colder cryovial wall.
The release of the latent heat will then further increase
the temperature lag between rim and core temperatures.
For vitrification protocols, the cooling rate needs to be
slow enough to achieve a homogeneous temperature dis-
tribution, especially around and below the glass transi-
tion temperature to not cause cracking [56].
Warming
It has been established that the quality of a biological
sample after cryopreservation depends not only on the
method of cooling, but also on the warming of the sam-
ple. (Note, we use the word “thawing” only in the con-
text of freezing. In vitrification, no ice crystals are
formed, and so the cells or tissues are technically not
frozen. Hence, it is more appropriate to use the word
“warming”). During warming, ice crystals can grow
around an initial nucleus. Both ice nucleation and
growth depend on temperature, yet in a different way.
The process of ice growth is fastest just below the freez-
ing point and attenuates when the temperature drops.
The nucleation reaches the peak well below the freezing
point. In other words, the cooled sample first passes
through an ice growth zone (but with few nuclei avail-
able to seed the growth), then, when the temperature for
crystallisation is no longer optimal, enters the zone of
nucleation. For this reason, rewarming the sample brings
more risk of recrystallisation and devitrification—when
the sample enters temperatures optimal for freezing, it is
already well nucleated [43]. This is also the reason why
the critical rates of cooling and rewarming necessary to
outpace the ice formation are different: the former must
deal with few nuclei, the latter with many [43]. Notably,
multiple small crystals (100–300 nm) [57, 58] are much
better tolerated than a few large ones. In this context, it
was demonstrated that the addition of a temperature
hold during rewarming at the glass transition
temperature can significantly alter the impact of physical
forces during warming for certain cell types [59]. It re-
mains to be investigated how to optimally choose the
dynamics of temperature changes during cooling and
warming, in a tissue-specific manner.
Recently, a novel method for warming has been tested
with promising results. Manuchehrabadi et al. demon-
strated that inductive heating of magnetic nanoparticles
can be employed to improve tissue cryopreservation
[60]. Other methods [61–65], like electromagnetic heat-
ing [60, 66–68], have also been proposed.
Nucleation temperature
The initial formation of ice crystals is only possible after
a primary nucleation event has occurred. If uncontrolled,
such primary nucleation is stochastic [69]. This means,
for example, when a specific aqueous sample is cooled at
a given cooling rate, it is not deterministic at what time
or temperature it will start freezing. The temperature at
which primary nucleation occurs within a sample is
called the nucleation temperature [70]. It has been
shown that the nucleation temperature affects cell sur-
vival in a similar way as the cooling rate does, namely, a
too high nucleation temperature can be detrimental to
cells caused by solution effects, whilst a too low nucle-
ation temperature, close to the spontaneous nucleation
temperature, can cause intracellular ice formation [70].
The highest survival of frozen cells was found at inter-
mediate nucleation temperature regimes [71]. It was fur-
ther found that at optimal intermediate nucleation
temperatures the concentration of CPAs could be re-
duced. In order to reduce the effects of toxic CPAs, the
active control of the nucleation temperature has been
proven to be beneficial for cell survival after thawing.
There are various methods for actively controlling the
process of nucleation for slow cooling [72, 73]. Briefly,
the nucleation temperature can be controlled by creating
locally supercooled conditions, such as via the applica-
tion of cooled metal rods, expanded gases [74] or Peltier
elements [75, 76]. Furthermore, ice-nucleating agents
(INAs) exist that can directly induce nucleation events,
with examples including silver iodide, ammonium sul-
fate, long-chain alcohols and nanoparticles [77]; how-
ever, as with CPAs, the utility of these is often limited by
their toxicity, availability or biocompatibility. Promis-
ingly, high-activity INA proteins have been discovered in
multiple frost-tolerant organisms, with the best charac-
terised being those from epiphytic bacteria of the genera
Pseudomonas and Erwinia [78–81]. The probability of a
primary nucleation can be increased by electrofreezing,
where a high electrical field is locally applied to a sample
[70, 76]. Other physical methods to control nucleation
include the use of ultrasound [82] or laser light pulses
[83], reviewed elsewhere [73].
Cryoprotective agents (CPAs)
As mentioned above, CPAs can prevent cryoinjury in
multiple ways, including the reduction of solution effects
[5, 55]. A good CPA should possess the following prop-
erties: it should be water-soluble at low temperatures
and to high concentrations, have good penetrance of cell
membranes and have low toxicity. The concentration-
dependent mechanisms of how pCPAs like DMSO and
EG benefit cryopreservation has been investigated
through simulations and experiments, which have sug-
gested that at intermediate CPA concentrations, pore
formation occurs within the membranes which increases
the hydraulic membrane permeability [84, 85].
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Some macromolecular CPAs like trehalose, dextran,
sucrose or hydroxyethyl starch, which do not permeate
cell membranes, are suggested to stabilise proteins by
the “preferential exclusion” effect [86]. It was found that
they prevent freezing damage best in combination with
pCPAs like DMSO [87]. Slow cooling studies revealed
that trehalose can alter the ice/cell interaction which can
improve post-thaw cell survival [88].
The usage of DMSO as a CPA was first described by
Lovelock and Bishop [4], 10 years after Polge et al.’s
work on the cryoprotective properties of glycerol [17].
DMSO offers the advantage of enhanced permeability vs.
glycerol for many cell types [89]. Currently, DMSO is
the most commonly used CPA for the storage of stem
cells [90]. However, the infusion of stem cells cryopre-
served with DMSO has been associated with toxic reac-
tions such as vomiting, cardiac dysfunction, arrhythmia
and others [90, 91].
Despite these advances in the identification and use of
CPAs, CPA toxicity remains the main challenge in cryo-
preservation [16]. Whilst the mechanisms of CPA toxicity
are only partially understood, some mechanisms have
been elucidated and classified as either specific or non-spe-
cific toxicity. Specific toxicity refers to CPA damage caused
through a mechanism unique to that particular CPA. For
example, EG is metabolised in the liver to glycolic acid,
causing metabolic acidosis [92]. Non-specific toxicity refers
to damage that occurs due to properties that CPAs have
in common. For example, CPAs form hydrogen bonds
with proteins; however, their bonding strength is higher
than that of water, with the potential to denature proteins
at high concentrations [93].
Importantly, the toxic effect of CPAs increases with
temperature. Loading ramp protocols where CPAs are
administered at increasing concentrations as the sample
is cooled can greatly improve post-warm viability. An-
other reason for using a loading ramp is to slowly equili-
brate the sample with the CPA to reduce osmotic stress
[43]. Indeed, the potentially lethal mechanical stresses
on cells due to CPA administration and removal are a
major current concern in cryobiology, particularly for
vitrification [94]. Moreover, nonequilibrium concentra-
tions of CPAs between regions of the sample [95] or
across the membrane [96, 97] can reduce the success of
cryopreservation.
Biological antifreeze proteins, compatible solutes and ice
blockers as alternatives
Some animals are known to produce substances that
allow them to survive cold temperatures by avoiding
ice formation [41, 98–100]. These substances can be
either cryoprotectants (e.g. glycerol) or antifreeze pro-
teins. The latter can bind to ice and hinder its growth
[43]; however, the use of such proteins is limited by
their high costs. Synthetic alternatives are used in re-
search. These include polyvinyl alcohol (PVA) as an
ice growth inhibitor, which binds to and prevents ice
crystals from getting larger, and polyglycerol (PGL) as
an ice nucleation inhibitor, which prevents ice from
nucleating in the first place (see Fig. 1) [43, 101,
102]. They are effective even in small quantities [101]
and widely used (examples [29, 103–108].
Compatible solutes are small organic osmolytes like
hydroxyectoine, ectoine and L-proline which are pro-
duced by microorganisms under stress. These have been
used to reduce the amount of pCPAs in freezing proto-
cols [109, 110]. There may be potential benefits in using
compatible solutes for vitrification methods.
Vitrification solutions
Vitrification solutions are used to decrease Vccr, allowing
larger samples to be vitrified. Pure water can be vitrified
if it is cooled fast enough, but to cause this, extremely
high cooling rates (in the order of 106 °C/s) are needed.
To counter this problem, high CPA concentrations can
be used to lower Vccr to a level achievable in practice by
plunging a sample into LN2. However, samples with a
high volume to surface area ratio exhibit a lower internal
cooling rate [111, 112].
To preserve larger tissues with a higher volume to sur-
face area ratio, vitrification solutions need to be made
more concentrated, or otherwise adapted to further
lower the Vccr. This often comes at the cost of increased
toxicity. As such, the development of vitrification solu-
tions is dependent on finding new CPAs or combina-
tions of CPAs that decrease Vccr whilst having lower
levels of toxicity [43]. A number of advances in vitrifica-
tion solutions have been made in recent years, as
follows.
Neutralising toxicity The simplest vitrification solu-
tions are high concentrations of single CPAs such as EG
or DMSO, which are toxic at high concentrations. It has
been found, however, that different CPAs can be com-
bined in a single solution to reduce toxicity. By using a
solution of different CPAs, it is possible to avoid using
any one CPA at a concentration that would cause spe-
cific toxicity. Additionally, certain CPAs can directly
neutralise the toxicity of other CPAs, for example,
DMSO neutralises the toxicity of formamide, allowing
for a higher total concentration of CPAs to be used with
reduced toxicity. This allows for a higher total CPA con-
centration for the same level of toxicity [44, 104].
Ethylene glycol It was found that using ethylene glycol
in vitrification solutions in place of PG reduces the non-
specific toxicity of the solution. This is because EG
forms weaker hydrogen bonds than propylene glycol,
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meaning that macromolecules are protected by increased
hydration from the greater number of remaining water
molecules [16, 104].
Non-penetrating CPAs (npCPAs) As discussed in "The
challenge of low temperatures" section, ice can form
more readily in the extracellular space than in the intra-
cellular space because the intracellular space has a
higher concentration of solutes [16]. For this reason, a
lower concentration of cryoprotectants is needed inside
the cell. High-molecular weight polymers that do not
penetrate cell membranes, such as polyvinylpyrrolidone
(PVP), can be used to mimic the effects of intracellular
solutes in the extracellular space, meaning that a lower
concentration of the more toxic penetrating cryoprotec-
tive agents (pCPAs) is needed for vitrification [7].
npCPAs also reduce chilling injury as the resulting solu-
tion is hypotonic.
Synthetic ice blockers Ice blockers are another kind of
npCPA which bind directly to ice and to heterogeneous
ice nucleators. These are the synthetic equivalent to
anti-freeze proteins [7]. Non-penetrating ice blockers
such as polyvinyl alcohol (PVA) are a cheaper and more
effective alternative to animal-derived antifreeze pro-
teins. Adding ice blockers in small amounts inhibits het-
erogeneous ice nucleation [43, 101].
Methoxylation M22 is an advanced proprietary vitrifica-
tion solution created by the company twenty-first Cen-
tury Medicine (21CM). The solution, described in Fahy
et al. [113], contains the methoxylated polyol 3-
methoxy-1,2-propanediol, which has increased cellular
permeability and decreased viscosity. This decreased vis-
cosity is important for vitrifying larger tissues and organs
because it increases the ability of the CPA to perfuse
into tissues. Additionally, 3-methoxy-1,2-propanediol in-
creases the glass transition temperature of tissues and
decreases the critical warming and cooling rates of the
solution [114, 115].
Hypertonicity Chilling injury can be reduced by making
hypertonic vitrification solutions, which have an in-
creased concentration of non-penetrating components
[113]. Whilst the reasons for the protective effect of
hypertonicity are poorly understood, it has been sug-
gested that it reduces damage due to the thermal con-
traction of cell membranes [116].
Current applications of cryopreservation
Organ preservation and banking
As mentioned in the “Organ and tissue preservation”
section, many thousands of lives worldwide would bene-
fit if replacing organs and tissues on demand became a
reality [25]. Some of the approaches to extend organ life-
time are ex vivo continuous perfusion at normothermic
temperatures (35–37 °C) and a combination of perfusion
with hypothermic temperatures (4–10 °C), which is rou-
tinely used for kidney transplants and can extend lung
survival times from 8 to 21 h [117]. The addition of
CPAs and suppression of ice formation (supercooling) in
rat livers enabled perfusion on even lower temperatures
(− 6 °C), extending storage times to 4 days [118]. How-
ever, so far, there are no effective methods to reliably
preserve solid organs beyond 3–12 h [119–121]. Not
only days or weeks but even hours of additional preser-
vation time would greatly increase the number of pos-
sible transplantations.
Kidneys and hearts have been the most widely stud-
ied organs, but neither has been consistently recov-
ered after cooling to temperatures lower than − 45 °C.
Nevertheless, sporadic survival of kidneys has been
claimed after cooling to lower temperatures [95, 113].
Along those lines, Fahy et al. reported success in vit-
rifying a rabbit kidney at − 130 °C which was
rewarmed using a special conductive warming tech-
nique combined with perfusion. After warming, the
kidney was transplanted into a recipient rabbit that
lived for 48 days with a working kidney before being
sacrificed [95]. More recently, Marco-Jimenez et al.
succeed in creating a long-term biobank of kidney
precursors as a potentially unlimited source of organs
for transplantation [122] as well as cryopreserving
renal primordia able to developed morphologically
normal glomeruli after warming and allotransplanta-
tion [123].
Tissue and cell banking
Corneal tissue
According to the WHO, 10 million people worldwide
require surgery to prevent corneal blindness as a re-
sult of trachoma, with a further 4.9 million suffering
from total blindness due to corneal scarring [124].
There is a considerable discrepancy between the sup-
ply and demand of transplantable corneas [125].
Even though currently the main problem in most
countries is the insufficient availability of transplant-
able corneas, corneal cryopreservation would con-
tribute to an amelioration of the situation. Moreover,
corneal tissue engineering is a highly researched
topic and has the potential to increase the supply.
Corneal cryopreservation would offer an unlimited
storage time and eliminate the time-dependent de-
terioration [126]. Human corneas for transplant are
commonly stored at 2–8 °C for up to 14 days, or by
organ culture, which allows up to 4 weeks of storage
[127]. The first cryopreservation technique developed
for rabbit, cat and human corneas used 7.5% DMSO
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and 10% sucrose. Although cryopreserved corneas
have been successfully transplanted, significant endo-
thelial damage occurred as a result of freezing [128].
Cells in monolayers, such as corneal endothelium,
are more susceptible to freezing injury compared to
isolated cells frozen in suspension. In human cor-
neas, endothelial cells have a very limited prolifera-
tive capacity, and cells lost during cryopreservation
are not subsequently replaced by mitotic division.
Well-preserved corneal endothelium is therefore cru-
cial to the successful outcome of full-thickness cor-
neal transplantation. A number of attempts have
been made to improve the reliability of corneal cryo-
preservation. Rabbit and human corneas have been
vitrified using 6.8 M propane-1,2-diol and shown to
retain endothelial function [128]. Although this tech-
nique showed some success, it requires exposure to
very high concentrations of solutes and is very time-
consuming. Recently, a cryopreservation protocol in-
volving interrupted slow cooling at 1 °C/min to a
plunge sub-zero temperature (− 35 °C for porcine
and − 45 °C for human) before storage in LN2, and
using a combination of a pCPA (5% DMSO) and a
npCPA (6% HES), has been successfully applied to
cryopreserve corneal endothelial cells [126]. So far,
however, cryopreserved human corneas have not
been adopted by eye banks for routine use due to
their significantly lower performance compared with
fresh corneas.
Retinal pigmented epithelium (RPE)
Transplantation of RPE may have a potential clinical ap-
plication for the treatment of RPE-specific retinal degen-
eration such as age-related macular degeneration
(AMD). AMD is the most common cause of blindness in
the developed world, affecting one in three people by 75
years of age [129] with an estimated prevalence of ∼600,
000 significantly visually impaired people in the UK and
over 8 million worldwide [130, 131]. The development
of a suitable storage method for RPE is necessary for the
establishment of future RPE replacement therapy [132].
The feasibility of an RPE storage bank has been investi-
gated by Durlu and Tamai who performed transplant-
ation of viable cryopreserved RPE cells into the
subretinal spaces of adult albino rabbits and 23-day-old
rats [133]. Successful transplantation was confirmed
postoperatively by light and electron microscopy. In rab-
bits, xenografted RPE cells residing on Bruch’s mem-
brane of the host retina were disclosed without any
morphologic difference between the fresh and cryopre-
served RPE cells in situ at day 25 following transplant-
ation [133]. In rats, subretinal injection of cryopreserved
RPE cells partially rescued photoreceptor cells locally at
the transplanted area as observed 3 months
postoperatively [133]. Together, their data confirmed
that cryopreserved RPE cells can be used for RPE
transplantation.
Although changes in viability, altered cellular functions
and impaired biological activities caused by cryopreser-
vation are usually transient, and cells resume their activ-
ities with time or after repeated passage, some
irreversible changes have also been reported. For ex-
ample, Basu et al. found an increase in abnormal chro-
mosomes in cultured bovine RPE cells after freezing,
which further increased after cell passage [134]. Another
study investigating RPE cell lines suggested that inappro-
priate freezing conditions may not only decrease cell via-
bility but also induce replicative senescence [135].
Valtink et al. also demonstrated that RPE cells can be
cryogenically stored and kept available for transplant-
ation for a prolonged period of time [136].
Retinal Müller glial cells cryopreservation
Müller cells are the dominant macroglia of the verte-
brate retina [137]. In addition to their various important
functional roles in retinal physiology, they are also in-
volved in retinal pathology, for example, the cells display
altered membrane properties in cases of proliferative
vitreoretinopathy [137, 138]. The use of human tissue is
limited by reasons of availability, thus developing a
method for long-term storage of these cells is desirable.
Biedermann et al. described a cryopreservation method
in which dissociated Müller cells are stored in 10%
DMSO. They showed that the main electrophysiological
properties were not altered by this method and that volt-
age- and ligand-gated currents can be recorded from
cryopreserved cells even after 2 years of storage [139].
Nerves and brain tissue
The replacement of damaged or missing cells is an
emerging treatment strategy for a number of neuro-
logical disorders. The cryopreservation of neural cells
and tissues has not been applied with sufficient success
to enable it to be incorporated into routine clinical prac-
tice. Isolated brain tissue has a short shelf-life and cells
are usually used for experiments immediately after isola-
tion or refrigerated for a short period of time before use.
Storage at 4 °C allows good survival of neural tissue up
to a maximum of 8 days [140–142]; therefore, develop-
ing long-term storage procedures is of vital importance.
Cryopreservation of primary neural cells would also
greatly facilitate basic neuroscience research [143]. The
ability to cryopreserve brain tissue would also facilitate
pooling of tissue from multiple donors, allowing plenty
of time for necessary testing to ensure safety and func-
tion of the cells prior to transplantation. Successful cryo-
preservation would be beneficial for neural tissue
engineering too, allowing long-term storage for purposes
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of inventory control, quality control and product distri-
bution [144].
The first attempts to achieve nerve tissue cryopreserva-
tion were published in 1953, by Luyet and Gonzales, who
demonstrated that chicken brain tissue survived freezing
to − 196 °C, following exposure to EG and rapid cooling
[145]. Since then, different studies have suggested meth-
odologies to cryopreserve neurons and neural stem cells
[146–154] as summarised by Paynter [147].
Many studies have measured the qualitative outcome of
viability [149, 150, 154] or cell membrane integrity [152];
however, only a few authors have characterised cryopre-
served cultures in deeper detail. Post-thaw viability (based
on membrane integrity assays) does not necessarily reflect
the quality of the cryopreservation procedure and proper
functionality tests must be carried out. For example, Hig-
gins et al. provided a qualitative evaluation of neuritic tree
formation [151] whilst Quasthoff et al. included a para-
metric analysis of morphological and functional develop-
ment of the cultures [153].
In addition, cryopreservation of organised adult cere-
bral tissue slices is of potential interest for pharmaceut-
ical neuropsychiatric drug evaluation and development.
Pichugin et al. showed that the viability and the struc-
ture of mature organised, and complex neural networks
can be well preserved by vitrification [29].
Cryopreservation of single neural cell suspension has
also been described, like neural progenitor cells [151,
154–157] and neurally differentiated pluripotent stem
cells [158]. Moreover, cryopreservation of brain spheroid
cultures is another emerging topic [148, 159, 160]. For
example, Ma et al. compared the survival rate and viabil-
ity after cryopreservation between three different states
of neural stem cells (NSC): single-cell suspension, NSC
spheres with diameters of 30–50 μm and 80–100 μm.
NSC spheres with a diameter of 80–100 μm achieved the
best survival rate of 82.9%, and the NSCs still sustain the
multi-differentiation potentiality [148].
Overall, efficient cryopreservation of neural tissue
would be beneficial not only to potential clinical use but
also for basic science and pharmaco-toxicology studies.
Tissue-engineered constructs banking
Cryopreservation of tissue-engineered products by main-
taining their structure and function is a prerequisite for
large-scale clinical applications. Since the engineered tis-
sue substitutes are undergoing clinical trials, and fore-
seeing a growing demand for cultured cells and tissues,
the tissue engineering community is becoming increas-
ingly worried about the challenge of providing sufficient
amounts of these products to the market [161]. Cryo-
preservation is the only established mechanism for long-
term preservation of cells, tissues and organs, as well as
engineered tissues; therefore, it is a key step for the im-
provement of tissue engineering.
Cryopreservation of retinal organoids
Nakano et al. showed that an optimised vitrification
method enables en bloc cryopreservation of stratified
neural retina (NR) of human origin [162]. They devel-
oped an efficient cryopreservation method for storing
stratified NR epithelia derived from human ESCs and
found that a vitrification method with pre-treatment in
10% DMSO + 5% EG + 10% sucrose on ice was quite ef-
fective for NR cryopreservation. More recent findings
show that both human iPSC-derived retinal organoids
and dissociated retinal cells can be easily cryopreserved
whilst retaining their phenotypic characteristics and the
preservation of photoreceptor precursors [163].
Cryopreservation of bioartificial liver
Hepatocyte microbeads can temporarily replace the
function of damaged hepatocytes in acute liver failure.
Hence, intraperitoneal transplantation of hepatocyte
microbeads is an attractive option for the management
of acute liver failure. Interestingly, alginate-encapsulated
hepatocyte spheroids were successfully cryopreserved by
Massie et al. [164]. More recently, Jitraruch et al. devel-
oped an optimised cryopreservation protocol that could
improve the outcome of cryopreserved hepatocyte
microbeads for future clinical use [165].
Cryopreservation of decellularised oesophagi for tissue
engineering
Efficient storage could potentially allow a timely use of
decellularised oesophagi, essential for oesophageal tissue
engineering and clinical translation. Recently, Urbani
et al. published a protocol for long-term storage of
decellularised oesophageal scaffolds for tissue engineer-
ing purposes which includes slow cooling with cryopro-
tectant solution in LN2 vapour [166].
Cryopreservation of tissue-engineered skeletal muscle
The tissue-engineered skeletal muscle plays an import-
ant role in the field of regenerative medicine and in
emerging areas such as soft robotics, organ-on-a-chip
disease models and drug testing [167]. Grant et al. pub-
lished an optimised protocol in which the tissue-
engineered skeletal muscle was frozen; tissue made from
either differentiated myotubes or their undifferentiated
myoblast precursors were investigated. After thawing the
tissue maintained cell viability, and moreover, an opti-
mised protocol in which the skeletal muscle was frozen
undifferentiated, showed a threefold increase in force
production as compared to unfrozen muscle [167].
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Cryopreservation of engineered neural tissue
The ability to preserve engineered neural tissue without
disrupting cellular and extracellular components and
structures is important for clinical translation and
commercialization. Of note, Day et al. studied the effect of
cryogenic preservation on engineered neural tissue [168].
Cryopreservation of tissue-engineered pancreatic substitute
The use of encapsulated insulin-secreting cells represents
a promising approach towards the treatment of insulin-
dependent diabetes. Mukherjee et al. investigated cryo-
preservation of a model tissue-engineered pancreatic sub-
stitute by two ice-free cryopreservation (vitrification)
solutions in comparison with a conventional freezing
protocol and found vitrification to be a promising preser-
vation procedure for this encapsulated cell system [169].
Cryopreservation of tissue-engineered bone
Yin et al. examined the feasibility of cryopreservation by
vitrification of tissue-engineered bone composed of
osteo-induced canine bone marrow mesenchymal stem
cells and partially demineralized bone matrix scaffold
and showed maintenance of cellular viability and osteo-
genic function after cryopreservation [170]. Recently,
Tam et al. compared the effects of two potential preser-
vation methods on the survival, quality and function of
human tissue-engineered bone grafts from iPSCs. They
found that storage at − 80 °C resulted in cell death and
structural alteration of the extracellular matrix, whilst
hypothermic storage at 4 °C did not significantly affect
tissue viability and integrity [171].
Cryopreservation of tissue-engineered skin
Tissue-engineered epidermal membranes are useful
for clinical wound healing. Chen et al. showed that
when transplanted into nude mice, trehalose-
cryopreserved artificial skin repaired skin defects in a
similar manner to a non-cryopreserved control [172].
Moreover, they showed that trehalose-cryopreserved
artificial skin resulted in engraftment and wound clos-
ure that was significantly enhanced compared with
that of DMSO-cryopreserved epidermal membranes
indicating that the use of trehalose improves cryo-
preservation of tissue-engineered epithelial sheets
[172].
Cryopreservation of tissue-engineered human dermal
replacement also plays an important role in skin tissue
engineering and skin banking. An optimal cryopreserva-
tion protocol consisting of a cooling rate at 1 °C/min in
10% DMSO with the viability of studied dermal equiva-
lent treated by this protocol being 75% of that of fresh
control was derived by Wang et al. [173].
Fertility cryopreservation
Fertility preservation (FP) is an important and rapidly
growing field of reproductive medicine. Since 1978,
when the first birth following in vitro fertilisation (IVF)
was reported, at least 8 million babies have been pro-
duced with the help of medically assisted reproduction
[174]. Cryopreservation techniques play a vital role in
this treatment revolution, allowing the long-term storage
of gametes and embryos without degradation of their
quality for later use [174]. With a growing number of
women postponing childbearing into their mid-thirties
and beyond, the need for FP treatment has never been
greater.
Beside elective FP available for healthy individuals, nu-
merous medical conditions that compromise fertility re-
quire special attention in terms of FP. Particularly
important is the need for FP in cancer patients. Most
cancer treatments like chemotherapy, radiotherapy or a
combination of both are highly toxic to the gonads and
can cause infertility in both male and female patients.
Non-malignant pathologies such as autoimmune dis-
eases and their treatment, benign haematological dis-
eases (most prominently β-thalassemia), gender
dysphoria prior to starting hormone therapy, gynaeco-
logical or urologic and some genetic disorders (Turner’s
syndrome, Fragile X syndrome, Klinefelter syndrome)
could also lead to impaired fertility [175–179].
Continuous improvements in cancer treatment and
early diagnosis significantly increased long-term survival
rates in cancer patients. Cancer survival statistics are
particularly impressive in children, with 80% of pre-
pubertal cancer patients (0–14 years) likely to survive
the disease [180, 181]. Survival rates in adolescent and
young adult cancer patients (15–39 years) also improved
dramatically in the last few decades [182]. Such an im-
provement in survival rates of cancer patients together
with advancements in assisted reproductive technologies
greatly increased the demand for FP for the childhood,
adolescent and young adult patients [183].
Methods for male fertility preservation
Successful semen cryopreservation was achieved first, in
the 1950s, thanks to their relative abundance for experi-
mentation and small size [174]. Although slow cooling
protocols can induce significant genetic damage, leading
to low post-thaw mobility rate [184], freezing techniques
for semen cryopreservation remain the most commonly
used worldwide [174]. Comparative studies between slow
cooling and vitrification showed that the use of vitrifica-
tion techniques is less damaging for DNA, slightly im-
proves post-warm motility rates and is more cost and
time-efficient [185–187]. Several studies confirmed that
long-term storage of sperm specimens (up to 40 years) did
not affect the post-warm fertilisation of sperm [188–190].
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However, a number of questions regarding the impact of
specific cryopreservation protocols and suitability of do-
nors are unresolved, and the research topic remains very
active and clinically relevant [191].
For prepubertal boys who have not undergone sperm-
atogenesis yet, and therefore not producing mature
sperm, testicular tissue biopsy and spermatogonial stem
cell cryopreservation is the only available option for fer-
tility preservation for boys who are undergoing fertility
reducing treatment such as chemotherapy. Germ cells
are removed and frozen before treatment and are trans-
planted back into testes after treatment to restore
spermatogenesis [192].
Methods for female fertility preservation
Embryo and oocyte cryopreservation are both well-
established FP techniques. Embryo cryopreservation is
the process of freezing and storing embryos at either
cleavage or blastocyst stage. This technique has been
proven as a safe and effective technology of FP over the
last four decades. Since the first birth after embryo cryo-
preservation reported in 1983, more than half a million
live births were achieved using this technique. Embryo
cryopreservation represents the gold standard for FP due
to high pregnancy rates [193, 194]. Importantly, human
embryos preserved by vitrification showed higher sur-
vival rates post-warm than embryos preserved using
slow cooling [195, 196].
Oocyte cryopreservation is the most widely used FP
technique in the world for delaying childbirth [197]. Oo-
cyte cryopreservation is technically more challenging
than embryo cryopreservation due to oocyte high water
content that makes it more prone to cryoinjury. There-
fore, oocyte cryopreservation involves a higher risk of
damage during the preservation process and results in
lower overall pregnancy rates compared to embryo cryo-
preservation [198]. Some of the adverse effects of oocyte
cryopreservation as summarised by Angarita et al. [193]
are hardening of the zona pellucida [199], egg’s meiotic
spindle, cytoskeleton and cortical granular damage by
ice crystals [200]. Lower survival rates were reported
after freezing of oocytes compared to vitrification as well
as lower fertilisation rates [201]. When compared to nat-
ural conception, the incidence of congenital anomalies
in born children does not differ significantly after cryo-
preservation [202].
Ovarian tissue cryopreservation is not a conven-
tional FP technique but is the only available option
for prepubertal girls and women who cannot delay
the start of cancer therapy [203]. It involves harvest-
ing and freezing of ovarian tissue allowing cryopreser-
vation of oocytes within the primordial follicles
presented in the ovarian cortex [193]. After thawing,
ovarian tissue can be either transplanted back into a
cancer survivor, or immature oocytes can be har-
vested and matured in vitro [194].
The first live birth after autotransplantation of previ-
ously frozen human ovarian tissue was reported in 2004
[204] with the number of live births exceeded 130 as of
June 2017 [203]. The majority of these pregnancies oc-
curred after natural conception, which is the main ad-
vantage of the ovarian tissue cryopreservation compared
to oocyte and embryo cryopreservation [205]. Besides
the restoration of fertility, the endocrine function of
ovarian tissue was also successfully restored with the
main duration of about 4–5 years after transplantation,
with graft functioning up to several years [206], making
this procedure an option to delay menopause [207].
Stem cell cryopreservation
The commercial and clinical application of stem cells re-
lies on cryopreservation as the only available long-term
storage option. Stem cells represent highly promising re-
sources for application in cell therapy and regenerative
medicine, drug discovery, toxicology and developmental
biology research [208]. Stem cell banking offers the op-
portunity to cryogenically preserve stem cells at their
most potent state for later use [209]. Many stem cells
come from once-in-a-lifetime tissues, like umbilical cord
blood (see 5.5.1.); therefore, all over the world, stem cell
banks are established in order to preserve these cells for
their potential clinical application or future use in basic
or translational research [208].
Umbilical cord blood (UCB) cryopreservation
Whilst UCB was treated as a medical waste in the
past, nowadays, it is used to treat various diseases
such as blood cancers as a valuable haematopoietic
stem cell source. Since the first successful transplant-
ation of cryopreserved UCB to treat an infant with
Fanconi anaemia was performed in 1988 [210], the
field of UCB banking and transplantation has grown
exponentially and a global network of public and pri-
vate biobanks of UCB was established [211]. By 2013,
over 600,000 UCB units have been stored for trans-
plantation worldwide, and more than 30,000 UCB
transplantations have been performed [212].
Human pluripotent stem cells cryopreservation
Due to their unlimited propagation and differentiation
abilities, human pluripotent stem cells including ESCs
and iPSCs are also attractive types of stem cells for
banking. Furthermore, iPSCs has opened up the poten-
tial for personalised cell therapies, and over the past dec-
ade, several initiatives have been established to collect
and generate a large amount of human iPSCs for scien-
tific research [213]. Many iPSC banks were established
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worldwide including the European Bank for induced
pluripotent Stem Cells (EBiSC).
Other available stem cell sources for banking include
bone marrow, umbilical cord tissue and adipose tissue.
Dental stem cells are also an easily accessible source of
multipotent adult stem cells [214] which makes them a
suitable alternative for bone marrow-derived mesenchy-
mal stem cells [215]. For that reason, dental tissues have
become an attractive source of mesenchymal stem cells
and dental stem cell banks are formed worldwide.
Haematopoietic stem cells cryopreservation
Haematopoietic progenitor cells (HPCs) are a highly
relevant from a clinical point of view. Notably, allo-
geneic haematopoietic stem cell transplantation
(HSCT) remains the only curative treatment for many
blood disorders and is the most established stem cell
treatment to date [216] Indeed, over the past 50 years,
HSCTs have been performed in over 400,000 individ-
uals. Along those lines, banking haematopoietic pro-
genitor cells (HPCs) from the bone marrow,
peripheral blood and umbilical cord blood is highly
important for facilitating the finding of matched do-
nors for patients needing HPC transplants. Cryo-
preservation of HPCs is the standard mode of
handling for HSCT but has certain disadvantages as
compared to the usage of non-cryopreserved HPCs
[217]. Hence, further research is needed to improve
the cryopreservation of this type of stem cells.
Avenues for future research and applications
Emergency medicine
Besides the medical applications described above that
are already being explored, improved capabilities for ar-
tificially lowering the temperature of biological tissue
could have a significant impact in many other fields. For
instance, the possibility to gain more time is crucial in
emergency medicine. Indeed, moderate states of
hypothermia are common in clinical practice. Along
those lines, therapeutic hypothermia has been associated
with beneficial outcomes in patients following out-of-
hospital cardiac arrest [218]. Moreover, animal studies
demonstrate improved neurological outcome [219, 220].
Such capabilities would be also advantageous in war-
zones, where availabilities of equipment and medical
staff are restricted, and so the extension of transfer time
would have a big impact. Furthermore, cryopreservation
of red blood cells is commonly used in settings where
their availability is limited or unpredictable [221]. Des-
pite these existent use cases, further research is required,
e.g. to establish critical parameters in hypothermic emer-
gency treatment, such as the duration, temperature and
the substances to be administered.
Space travel
Improved technologies for lowering the body
temperature would also be of major benefit for space
travel [222]. Currently, some of the most limiting factors
for manned, long-duration space travel (e.g. to Mars)
have to do with the requirements for keeping space trav-
ellers alive: beyond the availability of resources needed
for normal physiology and metabolism, there are also
significant health challenges posed by the long-term ex-
posure to interplanetary radiation and zero-gravity, as
well as the psychological stresses from confined space
and associated social dynamics. Low-temperature biosta-
sis or cryopreservation could render these issues negli-
gible. Along those lines, the European Space Agency
(ESA) and the US National Aeronautics and Space Ad-
ministration (NASA) have both investigated the feasibil-
ity of suspended animation for deep-space travel [223–
226]. Notably, it has been shown that rats (which are
non-hibernators) can be synthetically induced into a
hibernation-type state, namely torpor [227]. Torpor is a
state of reduced metabolic rate and decreased body
temperature. Intriguingly, it can protect from ionising
radiation, further highlighting the potential benefits of
this line of research for space travel.
Quantitative methods
With the advances in computing power in the last de-
cades, mathematical and computational approaches for
analysing and modelling processes have gained substan-
tial attraction in many biological fields (e.g. for omics,
brain dynamics or synthetic biology research). Also in
cryopreservation, quantitative methods have been useful
to formalise complex physical dynamics. Along those
lines, the seminal work of Mazur established that there
is an optimal cooling rate for different cell types, which
gave rise to mathematical equations describing the rela-
tionship between cell type-specific parameters and the
optimal cooling rate [6, 228] or the addition and removal
of CPAs [229]. More recently, such quantitative models
have been used to inform on the timing of addition and
removal of CPAs [230], as well as cooling rates and
plunge temperature [231].
Importantly, computer models can be applied at vari-
ous spatial scales and to varying detail: for instance,
Weng et al. [232] made use of molecular dynamics simu-
lations to assess the cryoprotective effect of different
CPA concentrations and temperatures. Such modelling
can help understand the impact of CPAs on a molecular
level, and so potentially guide rational CPA design. Also
making use of computational toolsets, but following a
complementary approach, Solanki et al. [59] employ a
computational model to study the volumetric properties
of thermo-mechanical stress on a much larger spatial
scale. Overall, it is anticipated that in the future, such
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computational methods will play an important role in
the design of cryogenic processing protocols for medical
applications, similar to current methods using
computer-aided design tools, and so constitute a valu-
able tool in cryopreservation, which currently is mainly
an experimental discipline.
Concluding remarks
Cryopreservation is an interdisciplinary endeavour be-
tween medicine, biology, bioinformatics, chemistry and
physics. The main challenges still to overcome are scal-
ing up current methods to larger volumes and complex
tissues. The larger the organ, or tissue volumes to be vit-
rified, correspondingly more time is required to cool and
warm the organ. Not only thermal conductivity is an
issue here but CPA viscosity limits for perfusion systems
play a role. The protocols for cell lines, or even small tis-
sues, such as sperm, eggs or corneas, cannot be repli-
cated in larger human organs, which necessitate toxically
high CPA concentration to inhibit ice formation during
the longer time spent between the melting temperature
and the glass transition temperature, and of course gives
more time for toxic insults to accumulate [233]. The
best techniques to get around these problems in small
tissues use combinations of CPAs to reduce toxic effects
of any single agent, using CPAs with weak water interac-
tions to minimise disruption of hydration layers around
biomolecules, using CPAs with mutual toxicity neutral-
isation effects, and reducing penetrating CPA concentra-
tions by adding non-penetrating CPAs and ice blockers.
Nonetheless, little is known about the mechanisms at
work.
The challenges in cryobiology are not insurmountable.
Future research will focus on ever more complex ways
to prevent ice formation and mitigate cryoprotectant
toxicity; novel cryoprotectants which exert dispropor-
tionately large cryoprotective effects compared to their
concentration, in silico molecular modelling, and en-
hanced understanding of the processes that occur during
cryopreservation will all be employed. One could envi-
sion a universal cryoprotectant solution, suitable for use
in a range of tissue types, and physical advancements en-
abling high cooling and warming rates, or the manipula-
tion of ice formation for large volume vitrification or
freezing.
Whilst the concepts have been long known, the
dedicated field of cryobiology dates back only around
70 years. In that time, it has advanced from freezing
spermatozoa using glycerol, to vitrifying tissues, and
even small organs using complex multi-component
solutions. This is remarkable progress given that cryo-
preservation is as yet a relatively niche field of study,
without garnering much attention in schools or
undergraduate courses and utilising a fraction of the
funding which is allocated to other causes. As such,
there are still many opportunities that lie ahead, from
short-term improvements in transplantation biology,
to ambitions that may once have been viewed as sci-
ence fiction, such as the building of organ banks or
long-term suspended animation.
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